Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Exclusion Criteria

• •Body mass index (BMI) \< 18.5 Kg/m\^2
• •Previous treatment for breast cancer including chemotherapy, endocrine therapy and radiotherapy; women with prior ductal breast carcinoma in situ (DCIS) who were treated with surgery only and whose treatment ended \>= 2 years prior to enrollment are eligible for the trial
• •Women who are planned to receive neoadjuvant therapy
• •Participants may not be receiving investigational agents
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Other co-existing invasive malignancies (with the exclusion of basal cell carcinoma or skin squamous cell carcinoma) diagnosed during the last 2 years before randomization
• •History of severe osteoporosis (T score =\< -4 either spine or hip), or presence of vertebral fracture
• •Use of systemic hormone replacement therapy (HRT) in the last 30 days prior to the randomization; the use of non-systemic estrogen (such as vaginal estrogen use) is allowed
• •Use of any chemopreventive agents (selective estrogen receptor modulators \[SERM\]) in the last 3 months
• •Concomitant use of CYP3A4 inducer medication (rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's wort)